Study of Heart and Renal Protection (SHARP)

Slides:

Advertisements

Similar presentations

Stephen P. McDonald, Graeme R. Russ Kidney International

Advertisements

Pathophysiology of renal fluid retention

LDL cholesterol in CKD—to treat or not to treat?

Beta blockers in the management of chronic kidney disease

Anemia management in chronic kidney disease

Volume 83, Issue 3, Pages (March 2013)

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure Steven Fishbane, Nobuyuki Miyawaki Kidney International

Progression of renal failure and hypertensive nephrosclerosis

Volume 63, Pages S88-S90 (June 2003)

Mortality caused by sepsis in patients with end-stage renal disease compared with the general population Mark J. Sarnak, Bertrand L. Jaber Kidney International

John P. Middleton, Patrick H. Pun Kidney International

Volume 77, Issue 1, Pages 6-8 (January 2010)

Volume 93, Issue 5, Pages (May 2018)

Pathophysiology of renal fluid retention

Need for better diabetes treatment for improved renal outcome

Homocysteine and risk in end-stage renal disease: a matter of context

George A. Kaysen, Burl R. Don

Early mortality in dialysis and adequacy of predialysis renal care: the picture is more complex than we thought Nicolas Rognant, Maurice Laville Kidney.

Volume 70, Issue 11, Pages (December 2006)

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

The epidemiology of chronic kidney disease

Edmund G. Lowrie Kidney International

Volume 73, Pages S5-S17 (April 2008)

LDL cholesterol in CKD—to treat or not to treat?

Acute myocardial infarction in patients with end-stage renal disease

Blood pressure targets in hemodialysis patients

Amit X. Garg, William F. Clark, R. Brian Haynes, Andrew A. House

Fructose intake as a risk factor for kidney stone disease

Volume 73, Issue 12, Pages (June 2008)

New insights in uremic toxins

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Microbiology and outcomes of peritonitis in North America

Nephrology in Latin America, with special emphasis on Brazil

Alternate-day dialysis may be needed for hemodialysis patients

Juan M. Lopez-Gomez, Eduardo Verde, Rafael Perez-Garcia

AGEs in foods: Do they play a role in uremia?

Non–high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease Yoshiki Nishizawa,

Volume 87, Issue 1, Pages (January 2015)

The kidney, a cardiovascular risk marker, and a new target for therapy

Counteracting progression of renal disease: A look into the future

Volume 80, Issue 6, Pages (September 2011)

Lynda Anne Szczech, Ira L. Lazar Kidney International

Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients Florian Kronenberg, Arno Lingenhel, Ulrich Neyer, Karl Lhotta, Paul König, Martin.

Volume 85, Issue 5, Pages (May 2014)

Prehypertension: is it relevant for nephrologists?

Homocysteine, renal function, and risk of cardiovascular disease

Volume 67, Pages S55-S62 (January 2005)

Volume 73, Issue 9, Pages (May 2008)

Stephen P. McDonald, Graeme R. Russ Kidney International

Volume 64, Issue 2, Pages (August 2003)

Daily nocturnal home hemodialysis

Carmine Zoccali, Francesca Mallamaci Kidney International

Taking a public health approach to the prevention of end-stage renal disease: The NKF Singapore Program Sylvia Paz B. Ramirez, Stephen I-Hong Hsu, William.

Current status of maintenance hemodialysis in Beijing, China

Atherosclerotic nephropathy

Volume 72, Issue 2, Pages (July 2007)

The Danish Renal Biopsy Register

Charles A. Herzog Kidney International

Yutaka Koda, M.D., Shin-Ichi Nishi, Masashi Suzuki, Yoshihei Hirasawa

Collecting and using patient and treatment center data to improve care: Adequacy of hemodialysis and end-stage renal disease surveillance1 William M.

Volume 75, Issue 7, Pages (April 2009)

Antioxidant therapy in hemodialysis patients: a systematic review

Evaluation of the Losartan in Hemodialysis (ELHE) Study

Ralf Dikow, Marcin Adamczak, Daniel Ernesto Henriquez, Eberhard Ritz

Relationship between advanced glycoxidation end products, inflammatory markers/acute-phase reactants, and some autoantibodies in chronic hemodialysis.

Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis Karl-Georg Fischer, M.D., Andreas van.

Morphology of the heart and arteries in renal failure

Asymmetric dimethylarginine: A cardiovascular risk factor in renal disease? Danilo Fliser, Jan T. Kielstein, Hermann Haller, Stefanie M. Bode-Böger Kidney.

Stephen Pastan, J. Michael Soucie, William M. McClellan

Presentation transcript:

Study of Heart and Renal Protection (SHARP) Colin Baigent, Martin Landry Kidney International Volume 63, Pages S207-S210 (May 2003) DOI: 10.1046/j.1523-1755.63.s84.4.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 (A) Associations between blood cholesterol and cardiovascular mortality, plotted on a logarithmic scale, among screenees in the Multiple Risk Factor Intervention Trial (MRFIT) with diabetes (N = 5000) and without diabetes (N = 340,000)6. (B) Associations between blood total cholesterol and all-cause mortality, plotted on a logarithmic scale, among 12,000 hemodialysis patients followed for one year7. Kidney International 2003 63, S207-S210DOI: (10.1046/j.1523-1755.63.s84.4.x) Copyright © 2003 International Society of Nephrology Terms and Conditions